-
iScience: Yong Chen's team reveals the molecular mechanism by which DPY30 promotes methyltransferase activity in the MLL complex
Time of Update: 2022-09-20
Recently, the Chen Yong Research Group of the Center for Excellence in Molecular and Cell Science (Institute of Biochemistry and Cell Biology) of the Chinese Academy of Sciences published in the journal iScience entitled: DPY30 acts as an ASH2L-specific stabilizer to stimulate the enzyme activity of MLL family methyltransferases on different Substrates' research paper reveals the molecular mechanism by which DPY30 promotes methyltransferase activity in the MLL complex.
-
Leuk Res: the main clinical response to the treatment of patients with cutaneous leukemia with bromine domain inhibitors PLX51107 and azacytidine
Time of Update: 2022-09-20
Overall, the response of patients to the treatment of skin diseases with PLX51107/AZA was an improvement in clinical response and overall well tolerated.
Overall, the response of patients to the treatment of skin diseases with PLX51107/AZA was an improvement in clinical response and overall well tolerated.
-
ESMO 2022: Efficacy and safety of osbutinib in combination with R-CHOP in patients with previously untreated non-GCB DLBCL
Time of Update: 2022-09-20
Resources:2022 ESMO: 627MO - Orelabrutinib plus RCHOP for previously untreated non-germinal center b cell-like (GCB) diffuse large b cell lymphoma (DLBCL) patients with extranodal disease
-
Leukemia Res: Anaggrel for thrombocytopenia in polycythemia vera: insights into practicality and safety outcomes from a large multicenter database
Time of Update: 2022-09-20
Prior to large prospective studies evaluating the role of ANA in PV, the researchers recommend that platelet-directed cytometry be used to consider patients with PV with bleeding risk and symptomatic thrombocytosis.
-
What are the bleeding disorders caused by common coagulation factor abnormalities?
Time of Update: 2022-09-20
(2) Typing: According to the genetic mode, clinical manifestations and results of laboratory tests, it can be roughly divided into three types: 1) Type I: mainly due to the reduction of the synthesis of vWF, while the structure of the vWF multimer is basically normal.
-
Nat Biotech: Producing 1 billion CAR-T cells at a time, the new CRISPR technology efficiently inserts ultra-long DNA sequences without the need for viral vectors
Time of Update: 2022-09-20
In this latest study, the research team developed a new CRISPR system that utilizes a single-stranded DNA (ssDNA) HDR template (HDRT) that binds to the Cas9 target sequence to achieve 2-3 times the knock-in efficiency and yield relative to dsDNA.
-
ESMO 2022: Prediction of growth centers, MYC/BCL2 protein bi-expression status, and MYC gene rearrangement in patients with diffuse large B-cell lymphoma (DLBCL) based on machine learning (LYSA study)
Time of Update: 2022-09-20
Patients were divided into four risk groups based on age, stage, serum lactate dehydrogenase (LDH) level, fitness status, and number of extranodal invasions, but with the addition of rituximab to the first-line chemotherapy regimen, the survival outcome of patients has changed significantly, and IPI does not distinguish DLBCL patients with different prognosis well.
-
Lancet Haematol: Clinically true data of Tisagenlecleucel in young children and infants with acute lymphoblastic leukemia
Time of Update: 2022-09-20
This is an international, multicenter, retrospective cohort study of children under 3 years of age with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
This is an international, multicenter, retrospective cohort study of children under 3 years of age with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
-
AJH: Clinical outcomes of MRD recurrence and role of therapeutic interventions after MRD-negative remission in AML patients
Time of Update: 2022-09-20
For patients with acute myeloid leukemia (AML), the cure rate is only 40-50% even if complete remission (CR) can be achieved after first-line therapy, confirming that many patients may have persistent
-
Elotuzumab in combination with pomadomide and dexamethasone for relapsed/refractory multiple myeloma: results from the final total survival analysis of the ELOQUENT-3 Phase II trial
Time of Update: 2022-09-15
1%）。 Table 2Compared with the Pd regimen, the EPd regimen significantly reduced the risk of death in patients previously treated with lenalidomide and a PI treatment of RRMM, with a median OS increase of 1 year.
-
Pola's three major offensive weapons (2) - CD79b innovative target accurately broke the game, DLBCL the world's first "magic bullet" to lead the new channel
Time of Update: 2022-09-15
GuideThe opening of every unknown world has been bravely foreseen by pioneers; Every journey of stealth in the dark of night, there are lighters fearlessly leading the way. The series of reports on "S
-
Research progress on ASCT pretreatment protocols for IMS 2022 Express MM patients
Time of Update: 2022-09-15
Therefore, this study compared the safety and efficacy of BUMEL and MEL200 as ASCT pretreatment regimens in NDMM patients receiving enhanced VRD (VRD-GEM) induction and consolidation therapy, giving patients 6 cycles of VRD-GEM first, followed by 2 cycles of VRD consolidation therapy after transplantation.
-
Focus on the frontier, deep interpretation, and chew the literature to get the essence of the "shower"
Time of Update: 2022-09-15
Highlights are presentedIn this paper, the three classic studies of CAR-T therapy, Belinda, ZUMA-7 and Transformer, were mainly analyzed to compare the efficacy and safety of second-line CAR-T therapy and standard treatment regimens in patients with high-risk relapsed/refractory large B-cell lymphoma (R/R LBCL).
-
IMS 2022 Voice of China Prof. Gang An's team: Induction therapy for multiple myeloma and advances related to autologous hematopoietic stem cell transplantation
Time of Update: 2022-09-15
As a result, Professor An gang's team conducted a prospective trial of 269 patients with NDMM who underwent iFISH testing after induction therapy with proteasome inhibitors or immunomodulators, of which 252 patients underwent MRD detection using multiparametric flow cytometry (MFC) (Figure 1).
-
The round table sent 5 experts to analyze the current situation of lymphoma diagnosis and treatment from 5 perspectives and look forward to the future development direction
Time of Update: 2022-09-15
For such patients, the combination of novel targeted drugs or cell therapies based on traditional second-line salvage chemotherapy regimens is expected to improve their response rates and give them the opportunity to receive ASCT to further improve efficacy.
-
Leading the future, targeting the style, and looking at the development trend of AML diagnosis and treatment from clinical practice and cutting-edge progress
Time of Update: 2022-09-15
Professor Wei HuiHow to integrate targeted drugs with chemotherapy and hematopoietic stem cell transplantation more effectively will be a hot topic in the field of AML, and further exploring the same feasible chemotherapy-free regimens as some hematological tumor areas, so as to truly achieve the goal of low-toxicity and high efficiency treatment, should also be the focus of AML's future attention.
-
Blood: Jianlin Qiao/Kailin Xu/Lingyu Zeng report on new mechanisms for platelet function and arterial thrombosis regulation
Time of Update: 2022-09-15
Recently, Professor Qiao Jianlin, Professor Xu Kailin and Professor Zeng Lingyu of the Institute of Hematology of Xuzhou Medical University, as co-corresponding authors, published a research paper entitled Protein tyrosine phosphatase PTPN22 negatively modulates platelet function and thrombus formation in the top journal blood in the field of hematology.
-
Waiting for : The consensus of the first CMV management experts in the field of allogeneic hematopoietic stem cell transplantation is coming!
Time of Update: 2022-09-14
Cytomegalovirus (CMV) infection is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which seriously threatens the prognosis and health of patients. In recent
-
Total cholesterol, triglycerides, LDL-C... Comprehensive interpretation of the four blood lipids!
Time of Update: 2022-09-14
In addition, patients with coronary heart disease stratify according to risk, with different lipid-lowering goals:High-density lipoprotein (HDL-C)■ Reference range: 1.
In addition, patients with coronary heart disease stratify according to risk, with different lipid-lowering goals:High-density lipoprotein (HDL-C)■ Reference range: 1.
-
[Nat Med] Tumor immune microenvironment plays a decisive role in car T treatment for large B-cell lymphoma
Time of Update: 2022-09-14
evaluated TME in patients with DLBCL who received CAR T (Axicabtagene ciloleucel, axi-cel) in the ZUMA-1 Phase II study, and the results showed that the immune content of TME was associated with clinical response, survival, and toxic outcomes.
